Gene · 28881
IGKV2D-30: immunoglobulin kappa variable 2D-30
12 sourcesgene-search-2026-11-11-0.2.0
Download JSON
Cite this record
ConductScience Library. IGKV2D-30: immunoglobulin kappa variable 2D-30. Genes, record 28881. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/28881
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| A0A075B6S6 | Immunoglobulin kappa variable 2D-30 | 120 | 0 | Ensembl, HGNC |
Source UniProt
Patents4
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,156
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | IGKV2D-30 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 8 | 2025 |
| R01NS105789 | Understanding GABAA receptor protein folding and misfolding | 8 | 2025 |
| R01AI049313 | T cell responses to CD1-restricted lipids in tuberculosis | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| R28AA012725 | Brain Tissue Resource Center for Alcohol Research | 4 | 2025 |
| T32AI007290 | Molecular and Cellular Immunobiology | 4 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 3 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 3 | 2025 |
| P30GM124165 | NE-CAT: A Resource for Advanced Macromolecular Crystallography | 3 | 2025 |
| T32AA007459 | Alcohol Intervention Treatment Outcome Research Training | 3 | 2025 |
1 to 10 of 2,156Source NIH's project files
See all 2,156 nih grantsPapers2,617
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody-Positive Myasthenia Gravis. | Eur J Immunol | 2026 | 41906599 | PubTator, text mining | PubMed |
| Anti-HLA antibodies in lung transplantation: diagnostic pitfalls and future directions. | Eur Respir Rev | 2026 | 41813012 | PubTator, text mining | PubMed |
| The potential of neuromelanin-sensitive MRI in psychiatric disorders. | Neurosci Appl | 2026 | 41809677 | PubTator, text mining | PubMed |
| Adaptations in Plasmodium tubulin determine distinct microtubule architectures, mechanics and drug susceptibility. | Nat Commun | 2026 | 41786731 | PubTator, text mining | PubMed |
| Thromboembolic events with olanzapine: a systematic review integrating meta-analysis and FAERS database. | Front Cardiovasc Med | 2026 | 41756513 | PubTator, text mining | PubMed |
| A fully human IgG1 antibody targeting MICA α1 domain inhibits interaction with NKG2D and activates immune effector functions against MICA-expressing cells. | Front Immunol | 2026 | 41756291 | PubTator, text mining | PubMed |
| Prevalence of Circulating Autoantibodies Against G-Protein-Coupled Receptors as Potential Biomarkers for Long COVID: Preliminary Investigations. | Int J Mol Sci | 2026 | 41751924 | PubTator, text mining | PubMed |
| Evolutionary remodeling of a remnant GET pathway factor into PEX38, an essential peroxin. | Proc Natl Acad Sci U S A | 2026 | 41746722 | PubTator, text mining | PubMed |
| Temporal Transcriptomics Leads From Discovery to in Vivo Validation: COL4A3/COL4A6/ COL4A5 and ITGA8 as Novel Arthrofibrosis Biomarkers in Post-traumatic Joint Contracture. | Dose Response | 2026 | 41743075 | PubTator, text mining | PubMed |
| Exploring the hypothetical role of cerebellar pain prediction errors in fibromyalgia-associated chronic pain. | Front Neurol | 2026 | 41738008 | PubTator, text mining | PubMed |
1 to 10 of 2,617
See all 2,617 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/28881
GET https://conductscience.org/api/genes/v1/28881/grants?page=2